Video

March 14, 2011

Dr. Fazel on Trends in Surgical Training

Author(s):

Maisam Fazel, FRCS, MS, MB BChir

Maisam Fazel, FRCS, MS, MB BChir, of Imperial College Healthcare NHS Trust in the United Kingdom on Trends in Surgical Training

Maisam Fazel, FRCS, MS, MB BChir, of Imperial College Healthcare NHS Trust in the United Kingdom on Trends in Surgical Training

Related Videos

Paolo Caimi, MD

Jennifer Scalici, MD

Steven H. Lin, MD, PhD

Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine

Victor Moreno, MD, PhD

Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec

Binod Dhakal, MD

Jill Corre, PharmD, PhD

Saad Z. Usmani, MD, MBA, FACP, FASCO

Related Content

Urothelial Cancer

November 16th 2024

Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment

Sebastian Kaulitzki – stock.adobe.com

November 14th 2024

2024 Updates in GI Cancer Feature FLOT Combinations, Restricted FDA Approvals by PD-L1 Expression, and More

CAR T Cells in R/R Non-Hodgkin Lymphoma | Image Credit: © Tatiana Shepleva - stock.adobe.com

November 14th 2024

Transposon-Based BAFF CAR T Cells Show Early Efficacy, Safety in R/R Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia

November 13th 2024

Piecing Together the Proper BTK Usage in CLL

Jennifer Amengual, MD, Herbert Irving Assistant Professor of Medicine, Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center

November 13th 2024

Real-World Experience With CAR T Varies From Trials in DLBCL

LASZLO – stock.adobe.com

November 13th 2024

BTK Inhibitors, CAR T-Cell Therapy Drive Paradigm Changes in Follicular Lymphoma

Related Content

Urothelial Cancer

November 16th 2024

Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment

Sebastian Kaulitzki – stock.adobe.com

November 14th 2024

2024 Updates in GI Cancer Feature FLOT Combinations, Restricted FDA Approvals by PD-L1 Expression, and More

CAR T Cells in R/R Non-Hodgkin Lymphoma | Image Credit: © Tatiana Shepleva - stock.adobe.com

November 14th 2024

Transposon-Based BAFF CAR T Cells Show Early Efficacy, Safety in R/R Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia

November 13th 2024

Piecing Together the Proper BTK Usage in CLL

Jennifer Amengual, MD, Herbert Irving Assistant Professor of Medicine, Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center

November 13th 2024

Real-World Experience With CAR T Varies From Trials in DLBCL

LASZLO – stock.adobe.com

November 13th 2024

BTK Inhibitors, CAR T-Cell Therapy Drive Paradigm Changes in Follicular Lymphoma

Latest Conference Coverage

Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL

Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment

Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer

Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC

View More Latest Conference Coverage

Editorial Board

MJH Life Sciences brands

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.